Corebridge Shorts Rebuild as Nippon Life Keeps Buying

CRBG is caught in a rare tug-of-war: short interest has jumped 32% over the past month while its largest shareholder keeps adding stock by the hundreds of thousands of shares each week.

Short positions have grown quickly since late September. ORTEX estimates 16.3 million shares short, equal to 3.1% of the free float, up from roughly 10.8 million at the end of September. That 30-day climb of 32% is fast for a stock this size. The weekly move is also notable: short positions rose 8.7% in the seven days to October 20, after a brief spike and partial unwind around October 15 when the estimate touched 17.4 million shares. The lending market, however, offers no amplification. Availability is 688%, meaning there are nearly seven shares available to borrow for every one currently lent out, well above the 52-week low of 235%. Cost to borrow sits at just 0.54%, down 15% on the week. Shorts are rebuilding positions with ease, not fighting a squeeze.

Options positioning has swung noticeably less defensive than usual. The put/call ratio dropped to 4.94 on October 20, more than two standard deviations below its 20-day mean of 5.64, the lowest relative reading in recent months. A falling PCR in this context means calls are gaining ground against a persistently put-heavy options structure. The 52-week PCR range runs from 0.09 to 6.53, so the absolute level is still put-dominated, but the direction of travel this week is toward less hedging rather than more.

Analyst sentiment is uniformly constructive and has been moving in one direction. TD Cowen raised its target to $40 from $38 this morning, maintaining Buy. Wells Fargo, Piper Sandler, Mizuho and Barclays all lifted targets between October 7 and October 12, with Barclays making the most aggressive move, from $33 to $39. UBS held its Neutral but raised its target to $36. The consensus target now sits at $40.42, representing about 16% above the current price of $34.95. The bull case rests on the Individual Retirement segment's bond gains and EPS estimates that reportedly run 5% above consensus for 2027. The bear case centres on equity market weakness squeezing fee income and hedging costs rising with rate volatility. Valuation is modest: price-to-earnings of 6.4 and price-to-book of 1.2 leave room for multiple expansion if earnings hold.

The most consequential ownership story belongs to Nippon Life Insurance. It holds a 13D activist position, now at 28.4% of the class following its latest amendment filed on October 6, up from 27.4% previously. The purchases have continued under a 10b5-1 plan through this month: the insurer bought shares on each of the last ten trading days reported, spending roughly $85 million in aggregate between October 7 and October 16 at prices ranging from $32.80 to $34.72. A plan-driven purchase carries less discretionary signal than an open-market decision, but the scale and consistency of the accumulation has taken Nippon Life's reported position to 129.5 million shares, 29.1% of the company. The net insider picture over 90 days is, by contrast, negative at roughly minus $223 million in value terms, though that figure is heavily influenced by Nippon Life's planned programme against earlier disposals elsewhere on the register.

The index picture adds a mechanical dimension. ORTEX forecasts an 84% probability that CRBG is deleted from the Russell 1000 and Russell 3000 at year-end, driven by the agreed takeover by EQH. ORTEX also puts an 80% probability on deletion from the S&P MidCap 400 and 65% on the MSCI World. Estimated dates are all around December 30 to 31, though the index providers have not yet confirmed them. For the MSCI World deletion, ORTEX estimates $562 million of forced selling, equivalent to 3.5 days of normal trading volume. EQH itself moved in lock-step with CRBG this week, up 1.7%, consistent with a deal-spread dynamic rather than independent price discovery.

Earnings are due November 2. The last three comparable prints produced a one-day move of minus 0.4%, plus 7.6% and plus 7.3% respectively, with five-day moves following the same directional bias. What the print clarifies, given the index deletion timeline and the 10b5-1 accumulation programme, is whether the business is generating the kind of earnings momentum that justifies the analyst community's unanimous target-raising of recent weeks.